Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Income from Continuing Operations (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Income from Continuing Operations data on record, last reported at 39170000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 3644.8% year-over-year to 39170000.0; the TTM value through Dec 2025 reached 143724000.0, down 319.09%, while the annual FY2025 figure was 143724000.0, 319.09% down from the prior year.
  • Income from Continuing Operations reached 39170000.0 in Q4 2025 per TRDA's latest filing, up from 44080000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 54989000.0 in Q2 2024 and bottomed at 44080000.0 in Q3 2025.
  • Average Income from Continuing Operations over 4 years is 11214062.5, with a median of 19510000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 452.52% in 2024, then tumbled 3644.8% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 24629000.0 in 2022, then soared by 61.25% to 9544000.0 in 2023, then surged by 111.58% to 1105000.0 in 2024, then crashed by 3644.8% to 39170000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 39170000.0 in Q4 2025, 44080000.0 in Q3 2025, and 43125000.0 in Q2 2025.